Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Additionally we are shipping PCSK9 Proteins (59) and PCSK9 Kits (53) and many more products for this protein.
Showing 10 out of 146 products:
Human Polyclonal PCSK9 Primary Antibody for WB - ABIN493159
Yue, Averna, Lin, Schonfeld: The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. in Human mutation 2006
Show all 4 references for ABIN493159
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009
Show all 3 references for ABIN453778
Human Polyclonal PCSK9 Primary Antibody for IHC (p), WB - ABIN782954
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Show all 3 references for ABIN782954
Human Polyclonal PCSK9 Primary Antibody for IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Show all 2 references for ABIN185371
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN652320
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004
Show all 2 references for ABIN652320
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN391505
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003
Show all 2 references for ABIN391505
Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
Possible inter-locus interactions among the DOCK7 (show DOCK7 Antibodies), PCSK9 and GALNT2 (show GALNT2 Antibodies) SNPs were also noted.
In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR (show HMGCR Antibodies) on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.
During sepsis, PCSK9 levels are highly correlated with the development of subsequent multiple organ failure. Inhibition of PCSK9 activity is an attractive target for treating the spectrum of sepsis and septic shock.
Report increased intestinal cholesterol absorption and elevated serum cholesterol in families with primary hypercholesterolemia without mutations in PCSK9.
Serum PCSK9 level is significantly elevated in coronary heart disease patients.
These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors.
Differences in lipid profiles between the Jing and Han populations might partially attribute to the DOCK7 (show DOCK7 Antibodies), PCSK9 and GALNT2 (show GALNT2 Antibodies) gene polymorphisms and their haplotypes determining different risk for the development of cardiovascular diseases.
High plasma PCSK9 levels are associated with type 2 diabetes.
PCSK9 could serve as a novel molecular biomarker for the non-invasive prenatal screening of neural tube defects.
the current meta-analysis highlighted that variant allele of OLR1 (show OLR1 Antibodies) rs11053646 G > C and PCSK9 rs505151 A > G may contribute to the susceptibility risk of ischemic stroke.
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
binding of PCSK9 to GRP94 (show HSP90B1 Antibodies) protects LDLR (show LDLR Antibodies) from degradation likely by preventing early binding of PCSK9 to LDLR (show LDLR Antibodies)
The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (show LDLR Antibodies) and VLDLR (show VLDLR Antibodies), which is determined by estradiol levels.
that ox-LDL receptor-1 (show OLR1 Antibodies) and PCSK9 positively influence each other's expression, especially during an inflammatory reaction
Data show that leptin (show LEP Antibodies) treatment suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9) in male, but fails to suppress PCSK9 in female.
The Liver Clock Controls Cholesterol Homeostasis through Trib1 (show TRIB1 Antibodies) Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR (show LDLR Antibodies)) Axis.
Hepatic LDLR (show LDLR Antibodies) levels are up-regulated in SEC24A (show SEC24A Antibodies)-deficient cells as a consequence of specific dependence of PCSK9, a negative regulator of LDLR (show LDLR Antibodies), on SEC24A (show SEC24A Antibodies) for efficient exit from the ensoplasmic reticulum.
PCSK9(-/-) mice display normal sodium balance and blood pressure regulation despite an increase of cleaved alphaENaC (show SCNN1A Antibodies) under basal condition
PCSK9-mediated CD36 (show CD36 Antibodies) degradation may serve to limit fatty acid uptake and triglyceride accumulation in tissues, such as the liver and adipose tissue.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9